Dosimetry-based high-activity therapy with
| Autor: | Jose, Genolla, Trinidad, Rodriguez, Pablo, Minguez, Ricardo, Lopez-Almaraz, Veronica, Llorens, Aizpea, Echebarria |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Risk Adolescent Remission Induction Chemoradiotherapy Progression-Free Survival 3-Iodobenzylguanidine Neuroblastoma Young Adult Treatment Outcome Drug Resistance Neoplasm Recurrence Child Preschool Disease Progression Humans Female Neoplasm Recurrence Local Child Radiometry Topotecan Retrospective Studies |
| Zdroj: | European journal of nuclear medicine and molecular imaging. 46(7) |
| ISSN: | 1619-7089 |
| Popis: | Patients with high-risk neuroblastoma have an increased risk of recurrence and relapse of disease and a very poor prognosis.Ten patients, between 3 and 20 years of age, were included. Nine patients had been refractory to several lines of chemotherapy and radiotherapy. One patient with a very high-risk neuroblastoma had received only induction therapy. Response was graded according to the International Neuroblastoma Staging System.Regarding treatment response, two patients achieved complete remission, one with relapse at 16 months, five achieved a partial remission, four showed progression at between 1 and 18 months; two showed stable disease with progression at between 1 and 5 months, and one showed progressive disease. Eight of the ten patients died with overall survival between 4 and 63 months, and two patients were still alive without disease at the time of this report: 52 and 32 months (patient had received only induction therapy). Acute and subacute adverse effects were mainly haematological, and one patient developed a differentiated thyroid cancer.In patients with high-risk refractory neuroblastoma, administration of high activities of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink